Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia

Haya Ascher-Svanum, Alan JM Brnabic, Anthony H Lawson, Bruce J Kinon, Virginia L Stauffer, Peter D Feldman, Katarina KelinLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USAAbstract: It is often difficult to determine whether a patient may best bene...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ascher-Svanum H, Brnabic AJM, Lawson AH, Kinon BJ, Stauffer VL, Feldman PD, Kelin K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/1a59ce1d9d3647b4ae4f1f2406b6344b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1a59ce1d9d3647b4ae4f1f2406b6344b
record_format	dspace
spelling	oai:doaj.org-article:1a59ce1d9d3647b4ae4f1f2406b6344b2021-12-02T02:36:04ZComparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia1176-63281178-2021https://doaj.org/article/1a59ce1d9d3647b4ae4f1f2406b6344b2012-03-01T00:00:00Zhttp://www.dovepress.com/comparison-of-patients-undergoing-switching-versus-augmentation-of-ant-a9497https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Haya Ascher-Svanum, Alan JM Brnabic, Anthony H Lawson, Bruce J Kinon, Virginia L Stauffer, Peter D Feldman, Katarina KelinLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USAAbstract: It is often difficult to determine whether a patient may best benefit by augmenting their current medication or switching them to another. This post-hoc analysis compares patients&rsquo; clinical and functional profiles at the time their antipsychotic medications were either switched or augmented. Adult outpatients receiving oral antipsychotic treatment for schizophrenia were assessed during a 12-month international observational study. Clinical and functional measures were assessed at the time of first treatment switch/augmentation (0&ndash;14 days prior) and compared between Switched and Augmented patient groups. Due to low numbers of patients providing such data, interpretations are based on effect sizes. Data at the time of change were available for 87 patients: 53 Switched and 34 Augmented. Inadequate response was the primary reason for treatment change in both groups, whereas lack of adherence was more prevalent in the Switched group (26.4% vs 8.8%). Changes in clinical severity from study initiation to medication change were similar, as indicated by Clinical Global Impressions&ndash;Severity scores. However, physical and mental component scores of the 12-item Short-Form Health Survey improved in the Augmented group, but worsened in the Switched group. These findings suggest that the patient&rsquo;s worsening or lack of meaningful improvement prompts clinicians to switch antipsychotic medications, whereas when patients show some improvement, clinicians may be more likely to try bolstering the improvements through augmentation. Current findings are consistent with physicians&rsquo; stated reasons for switching versus augmenting antipsychotics in the treatment of schizophrenia. Confirmation of these findings requires further research.Keywords: augmentation, drug substitution, polypharmacy, schizophrenia, switchingAscher-Svanum HBrnabic AJMLawson AHKinon BJStauffer VLFeldman PDKelin KDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2012, Iss default, Pp 113-118 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Ascher-Svanum H Brnabic AJM Lawson AH Kinon BJ Stauffer VL Feldman PD Kelin K Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
description	Haya Ascher-Svanum, Alan JM Brnabic, Anthony H Lawson, Bruce J Kinon, Virginia L Stauffer, Peter D Feldman, Katarina KelinLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USAAbstract: It is often difficult to determine whether a patient may best benefit by augmenting their current medication or switching them to another. This post-hoc analysis compares patients&rsquo; clinical and functional profiles at the time their antipsychotic medications were either switched or augmented. Adult outpatients receiving oral antipsychotic treatment for schizophrenia were assessed during a 12-month international observational study. Clinical and functional measures were assessed at the time of first treatment switch/augmentation (0&ndash;14 days prior) and compared between Switched and Augmented patient groups. Due to low numbers of patients providing such data, interpretations are based on effect sizes. Data at the time of change were available for 87 patients: 53 Switched and 34 Augmented. Inadequate response was the primary reason for treatment change in both groups, whereas lack of adherence was more prevalent in the Switched group (26.4% vs 8.8%). Changes in clinical severity from study initiation to medication change were similar, as indicated by Clinical Global Impressions&ndash;Severity scores. However, physical and mental component scores of the 12-item Short-Form Health Survey improved in the Augmented group, but worsened in the Switched group. These findings suggest that the patient&rsquo;s worsening or lack of meaningful improvement prompts clinicians to switch antipsychotic medications, whereas when patients show some improvement, clinicians may be more likely to try bolstering the improvements through augmentation. Current findings are consistent with physicians&rsquo; stated reasons for switching versus augmenting antipsychotics in the treatment of schizophrenia. Confirmation of these findings requires further research.Keywords: augmentation, drug substitution, polypharmacy, schizophrenia, switching
format	article
author	Ascher-Svanum H Brnabic AJM Lawson AH Kinon BJ Stauffer VL Feldman PD Kelin K
author_facet	Ascher-Svanum H Brnabic AJM Lawson AH Kinon BJ Stauffer VL Feldman PD Kelin K
author_sort	Ascher-Svanum H
title	Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
title_short	Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
title_full	Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
title_fullStr	Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
title_full_unstemmed	Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
title_sort	comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/1a59ce1d9d3647b4ae4f1f2406b6344b
work_keys_str_mv	AT aschersvanumh comparisonofpatientsundergoingswitchingversusaugmentationofantipsychoticmedicationsduringtreatmentforschizophrenia AT brnabicajm comparisonofpatientsundergoingswitchingversusaugmentationofantipsychoticmedicationsduringtreatmentforschizophrenia AT lawsonah comparisonofpatientsundergoingswitchingversusaugmentationofantipsychoticmedicationsduringtreatmentforschizophrenia AT kinonbj comparisonofpatientsundergoingswitchingversusaugmentationofantipsychoticmedicationsduringtreatmentforschizophrenia AT stauffervl comparisonofpatientsundergoingswitchingversusaugmentationofantipsychoticmedicationsduringtreatmentforschizophrenia AT feldmanpd comparisonofpatientsundergoingswitchingversusaugmentationofantipsychoticmedicationsduringtreatmentforschizophrenia AT kelink comparisonofpatientsundergoingswitchingversusaugmentationofantipsychoticmedicationsduringtreatmentforschizophrenia
_version_	1718402331140161536

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia

Ejemplares similares